Cue Biopharma, Inc. (CUE)
$19.57-20.48%Close
SELLCRISIS · day 17
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $51M
- Beta
- 2.63
- P/E (TTM)
- -0.72
- Short % float
- 26.93%
- Days to cover
- 1.1
- SI change
- +111.4%
- 1W
- -15.43%
- 1M
- -35.94%
- vs SPY 1W
- -15.29%
- vs SPY 1M
- -38.45%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 2
- GROWTH
- 24
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-
GROSS100
OP-262
NET-436
[VALUATION]
P/E TTM-0.72
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B53.72
P/FCF-
EV/EBITDA-1.40
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E381.26
ALTMAN Z-
CURR RATIO1.25
ND/EBITDA-
BETA2.63
Company news
FAQ
- What is LOPJLB’s current signal on CUE?
- LOPJLB’s latest quantitative signal on Cue Biopharma, Inc. (CUE) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CUE in?
- Cue Biopharma, Inc. (CUE) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Cue Biopharma, Inc. (CUE) do?
- Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion pr…